Cidofovir

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Substance from the group of virustatics.

Half-lifeThis section has been translated automatically.

17 or 65 h (metabolites).

IndicationThis section has been translated automatically.

Infections caused by cytomegaloviruses (including the untreated CMV retinitis), effective also against HSV and VZV.

Dosage and method of useThis section has been translated automatically.

Initial 5 mg/kg bw i.v. once/week for 2 weeks. Maintenance dose from week 3: 5 mg/kg bw i.v. once/14 days.

Remember!

Slow infusion for at least 1 hour. Due to the pronounced nephrotoxicity, administration of Probenicid 2 g three hours before and 1 g two and eight hours after Cidovofir. Immediately before the administration of cidofovir, 1 litre of 0.9% NaCl solution must be infused!

Undesirable effectsThis section has been translated automatically.

At systemic application: nausea, fever, alopecia, muscle pain.

Cave! Probenicide intolerance (exanthema, pruritus, nausea, vomiting, headache)

PreparationsThis section has been translated automatically.

Vistide

Authors

Last updated on: 29.10.2020